News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phage Biotechnology Corp. Engages The Bruckner Group to Find a Joint Commercialization Partner for Phage's Portfolio of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms



11/15/2007 9:10:00 AM

LAS VEGAS--(BUSINESS WIRE)--Phage Biotechnology Corp. (“Phage”) has engaged The Bruckner Group to find a partner to jointly commercialize Phage’s portfolio of recombinant biological therapies, the products of Phage’s development platforms and technologies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES